Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Mar 24;13:867190. doi: 10.3389/fneur.2022.867190

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Rechtman, Brill, Zveik, Uliel, Haham, Bick, Levin and Vaknin-Dembinsky.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Decreased Volume of CA4/DG at MOGAD patients compare to HCs. (A,B) Volume of hippocampal subfields of HCs (n = 21) and MOGAD patients (n = 18) analyzed by HIPS pipeline of Volbrain software. (A) Volumes of CA/DG4 (1.31 ± 0.18 vs. 1.14 ± 0.21, p = 0.009) and (B) SR/SL/SM (0.98 ± 0.14 vs. 0.82 ± 0.22, p = 0.008). (C) Volume of hippocampal subfields of monophasic (n = 6) and relapsing patients (n = 6), analyzed by HIPS pipeline of Volbrain software. (C) CA4/DG (0.98 ± 0.24 vs. 1.23 ± 0.14, p = 0.03) volume of MOGAD monophasic and relapsing course patients. MOGAD, Myelin oligodendrocyte glycoprotein antibody disorders; HCs, healthy controls. p * ≤ 0.05, ** ≤ 0.01.